CONCLUSION
At the most basic level, DIC is the excess activity
of thrombin. However, the clinical presentation
and therapy can differ greatly depending on
the primary cause. Both diagnosis and therapy
involve close coordination of laboratory data
and clinical assessment.
REFERENCES
1. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol
1998;59:65–73.
2. De Jonge E, Levi M, Stoutenbeek CP, Van Deventer SJH.
Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998;55:767–77.
3. Baker WF Jr. Clinical aspects of disseminated intravascular
coagulation: a clinician’s point of view. Sem Thrombosis
Hemostasis 1989;15:1–57.
4. Levi M, ten Cate H. Disseminated intravascular coagulation.
N Engl J Med 1999;341:586–92.
5. Gando S, Levi M, Toh CH. Disseminated intravascular
coagulation. Nat Rev Dis Primers 2016;2:16037.
6. Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol 2016;175: 12–23.
7. Sharma S, Mayberry JC, DeLoughery TG, Mullins RJ. Fatal
cerebroembolism from nonbacterial thrombotic endocarditis in a trauma patient: case report and review. Mil Med
2000;165:83–5.
8. Toh CH, Alhamdi Y, Abrams ST. Current pathological
and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med 2016;36:
505–12.
9. Yu M, Nardella A, Pechet L. Screening tests of disseminated
intravascular coagulation: guidelines for rapid and specific
laboratory diagnosis. Crit Care Med 2000;28:1777–80.
10. Mant MJ, King EG. Severe, acute disseminated intravascular
coagulation. A reappraisal of its pathophysiology, clinical
significance, and therapy based on 47 patients. Am J Med
1979;67:557–63.
11. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for
the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in
Haematology. Br J Haematol 2009;145: 24–33.
12. Levi M. Disseminated intravascular coagulation. Crit Care
Med 2007;35:2191– 5.
13. Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol
2016;174:503–14.
14. Gonzalez E, Moore EE, Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care
Clin 2017;33:119–34.
15. George JN. Clinical practice. Thrombotic thrombocytopenic
purpura. N Engl J Med 2006;354:1927–35.
16. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood
2000;96:1223–9.
17. Murrin RJ, Murray JA. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev
2006;20:51–60.
18. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017;129:2836–46.
19. Patton JF, Manning KR, Case D, Owen J. Serum lactate dehydrogenase and platelet count predict survival in thrombotic
thrombocytopenic purpura. Am J Hematol 1994;47:94–9.
20. Rock GA, Shumak KH, Buskard NA, et al. Comparison of
plasma exchange with plasma infusion in the treatment
of thrombotic thrombocytopenic purpura. N Engl J Med
1991;325:393–7.
21. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival
in thrombotic thrombocytopenic purpurahemolytic uremic
syndrome—clinical experience in 108 patients. N Engl J
Med 1991;325:398–403.
22. Kaplan BS, Trachtman H. Improve survival with plasma
exchange thrombotic thrombopenic purpura-hemolytic uremic syndrome. Am J Med 2001;110:156–7.
23. Kremer Hovinga JA, Coppo P, Lammle B, et al. Thrombotic
thrombocytopenic purpura. Nat Rev Dis Primers
2017;3:17020.
24. Asherson RA. The catastrophic antiphospholipid syndrome
[editorial]. J Rheumatol 1992;19:508–12.
25. Asherson RA, Piette JC. The catastrophic antiphospholipid
syndrome 1996: acute multi-organ failure associated with
antiphospholipid antibodies: a review of 31 patients. Lupus
1996;5:414–7.
26. Asherson RA, Cervera R. Castastrophic antiphospholipid
syndrome. Curr Opinion Hematol 2000;5:325–9.
27. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rhuem 2006;2:81– 9.
28. Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic
antiphospholipid syndrome: The current management
approach. Best Pract Res Clin Rheumatol 2016;30:239–9.
29. Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol
2016;28:218–27.
30. Hoffman JN, Faist E. Coagulation inhibitor replacement during sepsis: useless? Crit Care Med 2000; 28( 9 Suppl):S74–6.
31. Wada H, Asakura H, Okamoto K, et al. Expert consensus
for the treatment of disseminated intravascular coagulation
in Japan. Japanese Society of Thrombosis Hemostasis/DIC
subcommittee. Thromb Res 2010;125: 6–11.
32. Feinstein DI. Diagnosis and management of disseminated
intravascular coagulation: the role of heparin therapy. Blood
1982;60:284–7.
33. Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979;190:91– 9.
34. Stainsby D, MacLennan S, Hamilton PJ. Management of
massive blood loss: a template guideline. Br J Anaesth
2000;85:487–91.
35. Hébert PC, Wells G, Blajchman MA, et al. A multicenter,
randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409–17.
36. Blair SD, Janvrin SB, McCollum CN, Greenhalgh RM. Effect
of early blood transfusion on gastrointestinal haemorrhage.
Br J Surg 1986;73:783–5.
37. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med
2013;368: 11–21.
38. Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation
defects associated with massive blood transfusions. Ann Surg
1971;174:794–801.
39. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels
and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987;67:365–8.
BOARD REVIEW QUESTIONS
Test your knowledge of this topic.
Go to www.mdedge.com/jcso/hphemonc for
Board Review Questions on this topic.
